Hassanpour Mehdi, Salybekov Amankeldi A, Kobayashi Shuzo, Asahara Takayuki
Shonan Research Institute of Innovative Medicine, Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan.
Center for Cell Therapy and Regenerative Medicine, Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan.
Front Cell Dev Biol. 2023 Apr 17;11:1128134. doi: 10.3389/fcell.2023.1128134. eCollection 2023.
CD34 is a cell surface antigen expressed in numerous stem/progenitor cells including hematopoietic stem cells (HSCs) and endothelial progenitor cells (EPCs), which are known to be rich sources of EPCs. Therefore, regenerative therapy using CD34 cells has attracted interest for application in patients with various vascular, ischemic, and inflammatory diseases. CD34 cells have recently been reported to improve therapeutic angiogenesis in a variety of diseases. Mechanistically, CD34 cells are involved in both direct incorporation into the expanding vasculature and paracrine activity through angiogenesis, anti-inflammatory, immunomodulatory, and anti-apoptosis/fibrosis roles, which support the developing microvasculature. Preclinical, pilot, and clinical trials have well documented a track record of safety, practicality, and validity of CD34 cell therapy in various diseases. However, the clinical application of CD34 cell therapy has triggered scientific debates and controversies in last decade. This review covers all preexisting scientific literature and prepares an overview of the comprehensive biology of CD34 cells as well as the preclinical/clinical details of CD34 cell therapy for regenerative medicine.
CD34是一种细胞表面抗原，在包括造血干细胞（HSCs）和内皮祖细胞（EPCs）在内的众多干/祖细胞中表达，而这些细胞是已知的丰富的EPC来源。因此，使用CD34细胞的再生疗法已引起人们的兴趣，有望应用于患有各种血管性、缺血性和炎性疾病的患者。最近有报道称，CD34细胞可改善多种疾病中的治疗性血管生成。从机制上讲，CD34细胞既参与直接整合到扩张的脉管系统中，又通过血管生成、抗炎、免疫调节和抗凋亡/纤维化作用发挥旁分泌活性，从而支持发育中的微血管系统。临床前、试点和临床试验充分证明了CD34细胞疗法在各种疾病中的安全性、实用性和有效性记录。然而，在过去十年中，CD34细胞疗法的临床应用引发了科学辩论和争议。本综述涵盖了所有现有的科学文献，并对CD34细胞的综合生物学以及用于再生医学的CD34细胞疗法的临床前/临床细节进行了概述。
